(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/193746 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)
A61P 7/04 (2006.01)

(21) International Application Number:
PCT/US2025/019435

(22) International Filing Date:
11 March 2025 (11.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/564,458	12 March 2024 (12.03.2024)	US
63/647,966	15 May 2024 (15.05.2024)	US
63/661,008	17 June 2024 (17.06.2024)	US
63/713,022	28 October 2024 (28.10.2024)	US
63/745,261	14 January 2025 (14.01.2025)	US

(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 541-0045 (JP).

(72) Inventors; and

(71) Applicants: **ALLIKMETS, Kristina** [EE/US]; 59 Village Hill Road, Belmont, MA 02478 (US). **BERG, Deborah, T.** [US/US]; 174 Warner Hill Road, Derry, NH 03038 (US). **HOMSY, Jason** [US/US]; c/o Takeda Development Center Americas, Inc., 95 Hayden Avenue, Lexington, MA 02421 (US). **FEDYK, Eric** [US/US]; 120 Bigelow Drive, Sudbury, MA 01776 (US).

(74) Agent: **MACDOUGALL, Christina, A.** et al.; Morgan, Lewis & Bockius LLP, One Market, Spear Street Tower, San Francisco, CA 94105 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: DOSING REGIMENS OF ANTI-CD38 ANTIBODIES FOR TREATMENT OF SUBJECTS WITH IMMUNE THROMBOCYTOPENIA

(57) Abstract: Methods for treating subjects with autoimmune diseases such as immune thrombocytopenia (ITP) by administering isolated anti-CD38 antibodies are disclosed. Also disclosed are unit dosage forms for the anti-CD38 antibodies used in treating subjects with autoimmune diseases such ITP.

WO 2025/193746 A1